XENEXenon PharmaceuticalsXENE info
$39.35info-4.68%24h
Global rank4003
Market cap$2.96B
Change 7d-7.67%
YTD Performance-13.50%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Xenon Pharmaceuticals (XENE) Stock Overview

    Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

    XENE Stock Information

    Symbol
    XENE
    Address
    3650 Gilmore WayBurnaby, BC V5G 4W8Canada
    Founded
    -
    Trading hours
    -
    Website
    https://www.xenon-pharma.com
    Country
    🇨🇦 Canada
    Phone Number
    604 484 3300

    Xenon Pharmaceuticals (XENE) Price Chart

    -
    Value:-

    Xenon Pharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $39.35
    N/A
    Market Cap
    $2.96B
    N/A
    Shares Outstanding
    75.28M
    N/A
    Employees
    203.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org